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Lymphoid tyrosine phosphatase (LYP) and C-terminal Src kinase (CSK) are
negative regulators of signaling mediated through the T cell antigen receptor
(TCR) and are thought to act in a cooperative manner when forming a complex.
Here, we show that dissociation of the LYP/CSK complex is necessary for
recruitment of LYP to lipid rafts, where it down-modulates TCR-mediated
signaling. Our findings may also explain the reduced TCR signaling associated
with a single nucleotide polymorphism, which confers increased risk for
autoimmunity and results in the expression of a LYP allele that can no longer
bind CSK. Development of a potent and selective chemical probe of LYP allowed
us to confirm that the observed down-modulation of TCR-induced signaling was
due to the LYP catalytic activity. Our compound also represents a starting point
for the development of a LYP-based treatment of autoimmunity.
